Mike Nicoletti, Hunt Lawrence, and Jason Wallace dig into the looming Treasury market stress, proprietary-data risk in the age of frontier AI models, and a Medicare for All blueprint that could reshape healthcare investing. A 30-minute tour across energy, technology, and healthcare, anchored by this week’s Cash Flow Memo.
The Cashflow Memo
Key Takeaways
* Hunt puts better-than-even odds on a 2008-style Treasury market dislocation within 12-24 months as ~$2.5T of new government paper collides with the incoming Fed chair’s plan to run the balance sheet from ~$7T down to ~$1.5T, plus the financing wave funding AI data centers (SpaceX alone just did $25B of public debt after its equity raise).
* The only fiscal lever large enough to bend the deficit is healthcare, and Hunt floats Medicare for All run by an independent, Fed-style administrator (he names Dr. Oz) that ends the ~$600B/year Medicaid transfer to states; investment read is to avoid new healthcare positions broadly but identify the specific winners of a restructured system.
* Apple is running Apple Intelligence inference on Nvidia Blackwell inside Google Cloud (not TPUs) specifically because Nvidia uniquely offers encrypted-data-in-memory, making proprietary-data protection the new competitive axis for frontier-model compute.
* On a forced 5-year choice between Nvidia and Alphabet, the hosts lean Nvidia on relative value: ~$160B free cash flow trending toward ~$200B with minimal CapEx (vs. Apple’s $120B and Alphabet’s heavy capital program compressing its FCF), framed as the picks-and-shovels seller in the AI buildout.
* The memory-supply shortage is forcing Apple to raise device prices (an estimated +$275 on the iPhone Pro just to hold gross margin); Micron reports tonight, and the squeeze is driving a stack-wide efficiency push (Nvidia cites ~2.5x inference efficiency gains since OpenAI’s 5.5 models).
Show Notes
[00:26] Oil Holds in the 70s, and a Treasury Warning Hunt sees no change in the oil supply/demand picture, WTI holding around $71, and lower oil prices paradoxically supporting natural gas via reduced Permian growth. He lays out a better-than-50% case for a 2008-style Treasury dislocation in the next 12-24 months, with healthcare as the only spending lever big enough to matter.
[05:23] Medicare for All and Fixing Sick Care The hosts debate whether the U.S. can shift from triaging illness to keeping people healthy, why insurers’ one-year underwriting horizon works against long-term health, and how government’s interest in Medicare aligns with prevention.
[08:07] Proprietary Data in the Age of Frontier Models How do Lilly, Citadel, or a startup protect proprietary information when agents can analyze anything on the open internet? Apple’s choice to run inference on Nvidia Blackwell for encrypted-in-memory data, cloud providers’ security track record, and the new attack surface agents introduce.
[17:42] Nvidia vs. Alphabet for Five Years A forced one-stock choice: Alphabet as the chicken bet spanning search, cloud, Gemini, and DeepMind, versus Nvidia’s ~$160B-trending-$200B free cash flow on minimal CapEx. Plus the memory shortage forcing a ~$275 iPhone price hike and a stack-wide efficiency race.
[23:44] Healthcare Science: CRISPR, the FDA, and China A generalizable CRISPR approach that shreds cancerous tumor DNA, an FDA program to cut 6-12 months off Phase 1 trials by partnering biotechs with academic centers, and the competitive threat from faster-moving Chinese biotech.
[29:49] Closing: Medicare for All, the Fed, and the Financing Wave Dr. Oz as a Fed-style independent Medicare administrator, identifying the healthcare winners of a restructured system, and the collision of Treasury issuance with massive data-center financing (SpaceX’s $25B debt raise).
Download this week’s Cash Flow Memo at telltales.us, and subscribe for energy, tech, and healthcare insights every Wednesday.
Cashtags
$AAPL $AMZN $CHTR $CMCSA $GOOGL $LLY $MSFT $MU $NVDA $TGT $UPS $XOM
This post and the information herein are intended for informational purposes only. The views expressed herein are the author’s alone and do not constitute an offer to sell, or a recommendation to purchase, or a solicitation of an offer to buy, any security, nor a recommendation for any investment product or service. While certain information contained herein has been obtained from sources believed to be reliable, neither the author nor any of his employers or their affiliates have independently verified this information, and its accuracy and completeness cannot be guaranteed. Accordingly, no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, timeliness or completeness of this information. The author and all employers and their affiliated persons assume no liability for this information and no obligation to update the information or analysis contained herein in the future.
